NCT05981976View on ClinicalTrials.gov

A Study to Evaluate the Drug Levels of Abatacept Converted From Drug Substance by Two Different Processes in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

174

Participants

Timeline

Start Date

August 18, 2023

Primary Completion Date

December 14, 2023

Study Completion Date

December 14, 2023

Conditions
Healthy Participants
Interventions
BIOLOGICAL

Abatacept

Specified dose on specified days

Trial Locations (3)

33147

Local Institution, Miami

89113

Local Institution, Las Vegas

90630

Local Institution, Cypress

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT05981976 - A Study to Evaluate the Drug Levels of Abatacept Converted From Drug Substance by Two Different Processes in Healthy Participants | Biotech Hunter | Biotech Hunter